Full Press Release Details
argenx Reports Full Year 2022 Financial Results and Provides Fourth Quarter Business Update.
ARGX
argenx Reports Full Year 2022 Financial Results and Provides Fourth Quarter Business Update
Key Takeaway: argenx Reports Full Year 2022 Financial Results and Provides Fourth Quarter Business Update
Price reaction · baseline $366.02 (2023-02-28 close) · hit after-hours · 1 other ARGX headline(s) in the window, move may be shared
day 0 close
+0.8%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+36%
120-day peak, hindsight
Typical move
4.7%
average across 12 past catalysts
Lead asset
Empasiprubart
Phase 2 · AChR-Ab Seropositive Generalized Myasthenia Gravis